| abstract |
The present invention relates to an immunogenic fusion protein, wherein said protein comprises at least a first peptide consisting of an S protein from which a transmembrane domain located at the N-terminus of the isolate HBV is removed at the C-terminal side, isolate consists of a second peptide consisting of the ectodomain of the at least one membrane protein of HCV and the transmembrane domain. The subject of the invention is also a hybrid nucleic acid molecule encoding the fusion protein, a vector composed of the hybrid nucleic acid molecule, subviral particles composed of the fusion protein, at least the fusion protein, or at least the hybrid nucleic acid molecule, Or at least an immunogenic composition consisting of said subviral particles and a cell line which produces said fusion protein or said hybrid nucleic acid molecule or said subviral particles. |